Wockhardt to build manufacturing hub in India

By Emilie Reymond

- Last updated on GMT

Related tags Special economic zone India

Indian biopharmaceutical company Wockhardt has signed a deal with
Maharashtra Industrial Development Corporation (MIDC) to establish
a special economic zone (SEZ) in Aurangabad, India, in order to
expand its manufacturing capabilities.

A SEZ is a geographical region that has economic laws that are more liberal than a country's typical economic laws. Usually the goal is an increase in foreign investment. Special Economic Zones have been established in several countries, including China and India.

The new SEZ will be spread over 107 hectares of land where Wockhardt will set up a biopharmaceutical manufacturing and research facility.

"This SEZ will provide the base for a new thrust in international markets that will drive Wockhardt's growth in the coming years,"​ said Habil Khorakiwala, Wockhardt's chairman.

"It will make Aurangabad a major hub for pharmaceutical and biotechnology industries."

India has already a dominant role as an offshore location of choice for contract manufacturing and according to a recent KPMG report, its potential to further boost its strength presents an opportunity worth an estimated $48bn (€38bn) in 2007.

The SEZ will house manufacturing facilities for active pharmaceutical ingredients (API), biopharmaceuticals, and a research and development centre.

Wockhardt currently has ten manufacturing facilities, including one in the UK and while over half of the firm's sales now come from Europe and the US, India continues to be the group's manufacturing and research base.

Further investment in biotechnology at the proposed SEZ will accelerate Wockhardt's expanding global reach, the firm said.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Related suppliers

Follow us


View more